Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01627288
Other study ID # Pro00033820
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 4, 2012
Est. completion date November 16, 2019

Study information

Verified date February 2021
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date November 16, 2019
Est. primary completion date November 16, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Biopsy confirmed malignancy of the gynecologic tract - Involved pelvic or para-aortic lymph nodes - Treatment plan to include delivery of concurrent chemoradiotherapy. - Good performance status - Negative pregnancy test in women of child-bearing potential - Signed study-specific informed consent - Lab results within study specific limits Exclusion Criteria: - Prior radiation to the abdomen or pelvis - A history of Scleroderma or Inflammatory bowel disease - Contraindication to chemotherapy or radiation

Study Design


Intervention

Radiation:
Boost radiation
Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy

Locations

Country Name City State
United States Radiation Oncology, DUMC Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose of Integrated Boost Radiation Therapy, Administered With IMRT Technique With Concurrent Chemotherapy (Cisplatin). Concurrent radiation therapy and chemotherapy is the standard of care for node positive cervical cancer. While there are several acceptable means to boost the disease in the low pelvis (i.e. brachytherapy, IMRT, or external beam), there is limited research into boosting gross disease in the pelvis or para-aortic region. This protocol is designed to determine the maximum tolerated dose of treating tumor bearing regions within the abdomen and pelvis, using an integrated boost technique and concurrent chemotherapy. During RT to 6 weeks post RT
Secondary Time to Local-regional Control With Integrated Boost Radiation Therapy (TTLR) Local-regional control is defined as local control without any nodal recurrence. 3 years following treatment
Secondary Time to Distant Recurrence (TTDR) 3 years after treatment
Secondary Disease Free Survival (DFS) 3 years after treatment
Secondary Overall Survival (OS) 3 years after treatment
Secondary Number of Participants With Acute Dose Limiting Toxicities (DLT) Acute DLT will be defined based on the side effects inherent from radiation therapy for gynecologic cancers, including effects on bowel, bladder, and skin.Since integrated radiation dose escalation is unlikely to substantially affect the hematopoietic system, only non-hematologic, grade 3-4, acute toxicity will be considered the primary dose-limiting toxicity (acute DLT). Dose limiting toxicity will include any of the following during treatment or within 6 weeks of completion: Acute Grade 3-4 enteritis or proctitis, Acute Grade 3-4 bladder toxicity, Acute Grade 4 dermatologic toxicity. 6 weeks following treatment
Secondary Number of Participants With Late Dose Limiting Toxicities (DLT) Late DLTs will be defined at grade 3-4 GI or GU toxicity with onset after 6 weeks of treatment. 3 years following treatment
See also
  Status Clinical Trial Phase
Completed NCT00193830 - High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Phase 3
Recruiting NCT03403465 - Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Phase 2
Completed NCT01536392 - Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Phase 3
Completed NCT00510250 - A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer Phase 1/Phase 2
Not yet recruiting NCT05521997 - Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer Phase 2
Active, not recruiting NCT02328872 - Compass - Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia N/A
Recruiting NCT00292955 - Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Phase 2
Terminated NCT03318107 - Ultrasound and Photoacoustic Imaging for Cervical Cancer N/A
Recruiting NCT00122746 - Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients Phase 3
Recruiting NCT05975593 - MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Recruiting NCT04868097 - Predicting Adjuvant Post-operative Radiation Therapy in Patients With Cervical Cancer Stage IB2 N/A